MetLife Investment Management LLC Has $255,000 Position in Quanterix Co. (NASDAQ:QTRX)

MetLife Investment Management LLC increased its position in shares of Quanterix Co. (NASDAQ:QTRX) by 21.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,983 shares of the company’s stock after buying an additional 4,303 shares during the quarter. MetLife Investment Management LLC owned 0.06% of Quanterix worth $255,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of QTRX. Bank of New York Mellon Corp grew its stake in shares of Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company’s stock worth $1,150,000 after acquiring an additional 1,963 shares in the last quarter. Canada Pension Plan Investment Board grew its position in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock valued at $108,000 after purchasing an additional 4,000 shares in the last quarter. Invesco Ltd. increased its stake in Quanterix by 16.3% in the 4th quarter. Invesco Ltd. now owns 33,654 shares of the company’s stock valued at $358,000 after buying an additional 4,729 shares during the last quarter. Geode Capital Management LLC lifted its position in Quanterix by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 863,503 shares of the company’s stock worth $9,181,000 after buying an additional 4,836 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. acquired a new position in shares of Quanterix during the 4th quarter worth about $55,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Price Performance

NASDAQ:QTRX opened at $5.36 on Thursday. The firm’s fifty day moving average price is $6.22 and its two-hundred day moving average price is $9.20. The company has a market cap of $207.91 million, a P/E ratio of -5.06 and a beta of 1.12. Quanterix Co. has a one year low of $4.67 and a one year high of $19.18.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. As a group, equities research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on QTRX shares. Canaccord Genuity Group dropped their target price on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Leerink Partnrs cut Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Leerink Partners reissued a “market perform” rating and issued a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.20.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.